- Bernanke, In Key Speech, To Tackle Financial Stability
- Gap Profit Rises, Boosted by Improved Margins
- Best Trades Now: Energy, Defense, Food & More
- Why Markets Want Fannie, Freddie to Be Resolved
- Prescriptions for Fannie and Freddie
- Two Economic Indicators Show Continued Weakness
- Bonds Traders Prefer Fannie and Freddie Over Treasurys
- Jobless Claims Dip, But Overall Level Remains High
- Burger King Profit Up, Shares Fall on Margins
- Microsoft's $300 Million Makeover
- Barbie v. Bratz: Debating the Payout
- CSX 'Welcoming' Work With Activist Hedge Funds: CEO
- Heinz CEO: Ketchup 'Better Than Vodka' in Russia
- Video: Morningstar Anti-Recession Funds
- Segway Polo Nerds; Also: Your Mortgage Hardball E-Mails
- Hot Sauce, Tepid Stock?
- Cramer: Lehman's a 'Lurking Black Hole'
- Fast Money Now – Bove Upgrades Lehman, Other Mid-Day Trades for Thursday
Abbott wins OK for drug-coated heart stent
Topics:Pharmaceuticals
Companies:Abbott Laboratories
Font size:
Abbott Laboratories won U.S. approval to sell its drug-coated heart stent called Xience, the company said on Wednesday.
Xience is the newest entry in a multibillion-dollar market that includes devices sold by Johnson & Johnson , Boston Scientific and Medtronic Inc.
Abbott [ABT
Loading...
()
] said it plans to launch its stent immediately.
Copyright 2008 Reuters. Click for restrictions.
Tools:
Print
Email
Del.icio.us
Digg ItMORE FROM CNBC
Data is a real-time snapshot *Data is delayed at least 15 minutes